NFA
ABEO icon

Nationwide Fund Advisors’s Abeona Therapeutics ABEO Stock Holding History

Nationwide Fund Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-543
Closed -$231K – 17
2017
Q3 		$231K Hold
543
– – ﹤0.01% 2568
2017
Q2 		$87K Buy
+543
New +$74.1K ﹤0.01% 2957
2016
Q2 		– Sell
-264
Closed -$17K – 3262
2016
Q1 		$17K Hold
264
– – ﹤0.01% 3104
2015
Q4 		$22K Hold
264
– – ﹤0.01% 3068
2015
Q3 		$27K Hold
264
– – ﹤0.01% 3097
2015
Q2 		$33K Buy
+264
New +$39.7K ﹤0.01% 3131

Other funds holding ABEO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

Nationwide Fund Advisors's ABEO Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Abeona Therapeutics (ABEO) in Q4 2017, closing a stake of 543 shares — an estimated $231K sold.

Nationwide Fund Advisors first reported a position in ABEO in Q2 2015 and held it in 6 quarters. The position peaked at $231K in Q3 2017. 93 funds tracked by Wall St. Rank hold ABEO as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Abeona Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 543 Abeona Therapeutics shares in Q4 2017, an estimated $231K.
  • Nationwide Fund Advisors first reported a position in Abeona Therapeutics in Q2 2015 and held it in 6 quarters.
  • Nationwide Fund Advisors's Abeona Therapeutics position peaked at $231K in Q3 2017.
  • 93 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.